ArticleNature communications2022
Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 78 citations in OpenAlex.
- Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions.Drug delivery · 2026Review
- Tailoring virus-inspired nanoparticles for advanced drug and gene delivery.Materials today. Bio · 2026Review
- Nanochirality-programmed type-I photosensitizer enables deep-tumor photodynamic therapy by reducing extracellular-matrix adhesion.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Self-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics.RSC advances · 2026Review
- Thermo-responsive targeting of polymeric micelles by controlling the cellular uptake based on the change of their surface arginine density.Communications chemistry · 2025Article
- Site-specific adaptive nanovesicles for oral insulin delivery.Science advances · 2025Article
- All-in-one peptide with sequential pH gradient sensing capabilities for the targeted delivery and deep penetration of nanomicelles against breast cancer.Asian journal of pharmaceutical sciences · 2025Article
- An Effective Oral Nanodelivery Material for Curcumin: Ingenious Utilization of Gastrointestinal Absorption Characteristics.Molecules (Basel, Switzerland) · 2025Article
- Nanoparticles with Cell-Penetrating Peptides for Oral Delivery: A Case for Oral Delivery of Insulin.International journal of nanomedicine · 2025Review
- Functional Liposomes Improve the Oral Absorption of Lurasidone Hydrochloride by Overcoming Multiple Absorption Barriers and Eliminating Food Effect.International journal of nanomedicine · 2025Article
- Exploring the potential of polymers: advancements in oral nanocarrier technology.Beilstein journal of nanotechnology · 2025Review
- An orally administered glucose-responsive polymeric complex for high-efficiency and safe delivery of insulin in mice and pigs.Nature nanotechnology · 2024Article
- Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties.Journal of nanobiotechnology · 2024Review
- Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation.Acta pharmaceutica Sinica. B · 2024Review
- Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Nanostructure-Mediated Transport of Therapeutics through Epithelial Barriers.International journal of molecular sciences · 2024Review
- Artificial viruses: A nanotechnology based approach.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives.Acta pharmaceutica Sinica. B · 2024Review
- Mitochondria-associated membranes contribution to exercise-mediated alleviation of hepatic insulin resistance: Contrasting high-intensity interval training with moderate-intensity continuous training in a high-fat diet mouse model.Journal of diabetes · 2024Article
- Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutual interference between surface ligands on multifunctional nanoparticles remains a significant obstacle to achieving optimal drug-delivery efficacy. Here, we develop ligand-switchable nanoparticles which resemble viral unique surfaces, enabling them to fully display diverse functions. The nanoparticles are modified with a pH-responsive stretchable cell-penetrating peptide (Pep) and a liver-targeting moiety (Gal) (Pep/Gal-PNPs). Once orally administered, the acidic environments trigger the extension of Pep from surface in a virus-like manner, enabling Pep/Gal-PNPs to traverse intestinal barriers efficiently. Subsequently, Gal is exposed by Pep folding at physiological pH, thereby allowing the specific targeting of Pep/Gal-PNPs to the liver. As a proof-of-concept, insulin-loaded Pep/Gal-PNPs are fabricated which exhibit effective intestinal absorption and excellent hepatic deposition of insulin. Crucially, Pep/Gal-PNPs increase hepatic glycogen production by 7.2-fold, contributing to the maintenance of glucose homeostasis for effective diabetes management. Overall, this study provides a promising approach to achieving full potential of diverse ligands on multifunctional nanoparticles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.